目的 系統(tǒng)評(píng)價(jià)補(bǔ)益強(qiáng)心片聯(lián)合治療慢性心力衰竭（CHF）患者療效及安全性。方法 檢索中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（CBM）、萬(wàn)方數(shù)據(jù)庫(kù)（Wanfang Date）、維普中文科技期刊數(shù)據(jù)庫(kù)（VIP）、PubMed、Embase、Cochrane Library、Medline等數(shù)據(jù)庫(kù)自建庫(kù)至2022年5月收錄的補(bǔ)益強(qiáng)心片聯(lián)合治療CHF臨床隨機(jī)對(duì)照試驗(yàn)（RCT），采用RevMan 5.4.1及Stata 15.0軟件進(jìn)行Meta分析。結(jié)果 納入13項(xiàng)RCTs，共1 570例患者，其中試驗(yàn)組874例、對(duì)照組696例。Meta分析結(jié)果顯示，與對(duì)照組比較，試驗(yàn)組可能明顯提高CHF患者的臨床有效率[RR=1.16，95% CI （1.11，1.22）]，改善射血分?jǐn)?shù)[MD=4.63，95% CI （4.08，5.18）]，降低N-末端腦鈉肽前體[SMD=-2.02，95% CI （-3.02，-1.02）1，增加6 min步行距離[MD=41.34，95% CI （37.50，45.18）]，降低明尼蘇達(dá)心力衰竭生活質(zhì)量量表評(píng)分[MD=-9.54，95% CI （-10.80，-8.28）]，改善L氏心衰評(píng)分[MD=-1.09，95% CI （-1.36，-0.83 1，兩組有顯著差異（P<0.00001）；降低不良反應(yīng)[RR=0.28，95% CI （0.12，0.66），P=0.004]。結(jié)論 補(bǔ)益強(qiáng)心片聯(lián)合西醫(yī)常規(guī)治療較單純西醫(yī)常規(guī)治療CHF具有更好的療效和安全性，但限于納入文獻(xiàn)質(zhì)量低等不足，需進(jìn)一步研究加以驗(yàn)證。

Objective To systematically evaluate the clinical efficacy and safety of Buyi Qiangxin Tablets combination therapy for patients with chronic heart failure(CHF).Methods Data were electronically searched from the CNKI, CBM, WanFang, VIP, PubMed, Embase, Cochrane Library, Medline database to collet randomized controlled trails(RCTs) of Buyi Qiangxin Tablets combination therapy for CHF.The retrieval time was from database establishment to May 2022.Meta-analysis was performed using RevMan 5.4.1 and Stata 15.0 software.Results A total of 13 RCTs were included, including 1 570 patients which 874 cases in experimental groups and 696 cases in control groups.Meta-analysis results showed that compared with control group, experimental can significantly improve the clinical efficiency[RR=1.16, 95%CI(1.11, 1.22)], improve the ejection fraction values[MD=4.63, 95%CI(4.08, 5.18)], reduce NT-proBNP[SMD=-2.02, 95%CI(-3.02, -1.02)], extend the distance of 6-minute walk distance[MD=41.34, 95%CI(37.50, 45.18)], reduce the Minnesota heart failure quality of life scale score[MD=-9.54, 95%CI(-10.80, -8.28)], improve L's heart failure score[MD=-1.09, 95%CI(-1.36, -0.83)], which were statistically significant(P<0.000 01);and reduce adverse reactions[RR=0.28, 95%CI(0.12, 0.66), P=0.004].Conclusion The combination of western medicines and Buqi Qiangxin Tablets in combination treatment of CHF has good efficacy and safety over western medicines alone.However, due to the low quality of inclusion literatures and other limitations, more studies are indeed in the future.

R286.2;R972